Raras
Buscar doenças, sintomas, genes...
Deficiência de fator II congênita
ORPHA:325CID-10 · D68.2CID-11 · 3B14.ZOMIM 613679DOENÇA RARA

A deficiência de Fator II, que é de nascença, é um distúrbio de sangramento hereditário (passado de pais para filhos). Ela ocorre porque a atividade do Fator II (também conhecido como protrombina) está diminuída, e se manifesta por sangramentos na pele e nas mucosas (como na boca e no nariz).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A deficiência de Fator II, que é de nascença, é um distúrbio de sangramento hereditário (passado de pais para filhos). Ela ocorre porque a atividade do Fator II (também conhecido como protrombina) está diminuída, e se manifesta por sangramentos na pele e nas mucosas (como na boca e no nariz).

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.05
Europe
Início
All ages
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: RS, PR, SC, PA, PE +10CID-10: D68.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
15 sintomas
🫘
Rins
1 sintomas
💪
Músculos
1 sintomas
🦴
Ossos e articulações
1 sintomas
🫃
Digestivo
1 sintomas

+ 10 sintomas em outras categorias

Características mais comuns

90%prev.
Antígeno de protrombina reduzido
Muito frequente (99-80%)
90%prev.
Tempo de tromboplastina parcial prolongado
Muito frequente (99-80%)
90%prev.
Tempo de protrombina prolongado
Muito frequente (99-80%)
55%prev.
Hemorragia intracraniana
Frequente (79-30%)
55%prev.
Hemorragia articular
Frequente (79-30%)
55%prev.
Epistaxe
Frequente (79-30%)
29sintomas
Muito frequente (3)
Frequente (4)
Ocasional (12)
Muito raro (2)
Sem dados (8)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 29 características clínicas mais associadas, ordenadas por frequência.

Antígeno de protrombina reduzidoReduced prothrombin antigen
Muito frequente (99-80%)90%
Tempo de tromboplastina parcial prolongadoProlonged partial thromboplastin time
Muito frequente (99-80%)90%
Tempo de protrombina prolongadoProlonged prothrombin time
Muito frequente (99-80%)90%
Hemorragia intracranianaIntracranial hemorrhage
Frequente (79-30%)55%
Hemorragia articularJoint hemorrhage
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos105publicações
Pico202114 papers
Linha do tempo
2026Hoje · 2026🧪 1992Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

F2ProthrombinDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces (PubMed:2019570, PubMed:21976677). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells (PubMed:3056

LOCALIZAÇÃO

Secreted, extracellular space

VIAS BIOLÓGICAS (10)
Thrombin signalling through proteinase activated receptors (PARs)Common Pathway of Fibrin Clot FormationIntrinsic Pathway of Fibrin Clot FormationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)Defective F8 cleavage by thrombin
MECANISMO DE DOENÇA

Factor II deficiency

A very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. The severity of the bleeding manifestations correlates with blood factor II levels.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
599.6 TPM
Cérebro - Hemisfério cerebelar
1.7 TPM
Cerebelo
1.6 TPM
Testículo
1.4 TPM
Artéria tibial
0.6 TPM
OUTRAS DOENÇAS (5)
congenital prothrombin deficiencythrombophilia due to thrombin defectcerebral sinovenous thrombosisobsolete susceptibility to ischemic stroke
HGNC:3535UniProt:P00734

Medicamentos aprovados (FDA)

5 medicamentos encontrados nos registros da FDA americana.

💊 ALTUVIIIO (ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL)
💊 ROCTAVIAN (VALOCTOCOGENE ROXAPARVOVEC-RVOX)
💊 REBINYN (COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED)
💊 Alhemo (CONCIZUMAB)
💊 Hemlibra (EMICIZUMAB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

71 variantes patogênicas registradas no ClinVar.

🧬 F2: NM_000506.5(F2):c.1130+1G>A ()
🧬 F2: NM_000506.5(F2):c.119G>A (p.Arg40Gln) ()
🧬 F2: NM_000506.5(F2):c.552del (p.Val185fs) ()
🧬 F2: NM_000506.5(F2):c.1750C>T (p.Gln584Ter) ()
🧬 F2: NM_000506.5(F2):c.1741C>T (p.Arg581Cys) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Deficiência de fator II congênita

Centros de Referência SUS

24 centros habilitados pelo SUS para Deficiência de fator II congênita

Centros para Deficiência de fator II congênita

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Adiposity rebound and height velocity in patients with Congenital Adrenal Hyperplasia.

European journal of endocrinology2026 Mar 13

Adiposity rebound is the first rise in BMI that occurs after the initial decrease during infancy. Early adiposity rebound, before age 5, is a risk factor for later obesity and metabolic problems. We investigated adiposity rebound in children with Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency (CAH). Longitudinal observational registry study. Height, weight and BMI from patients younger than 20 years in the I-CAH Registry was described by non-linear mixed-effects models. Covariates of glucocorticoid dose, mineralocorticoid dose, 17-Hydroxyprogesterone were assessed on growth and bone age. A total of 10,261 visits within 573 patients (43.6% male) showed significant variation in age at latest peak height velocity (8.4 years (SD = 3.0) in boys; 9.0 years (SD = 1.6) in girls). Peak height velocity was more blunted in boys (7.7 cm/year (SD = 1.4)) than girls (7.4 cm/year (SD = 1.3)) in comparison to normative values. Adiposity rebound occurred earlier than age 5 years in 82% of the cohort, mean age 3.7 years (SD = 1.3) in boys and 3.9 years (SD = 0.9) in girls. Girls prescribed higher doses of glucocorticoid were associated with heavier weight in adolescence and earlier adiposity rebound. Bone age was increasingly advanced in those prescribed higher doses in both sexes. There is a large variation in the timing of adiposity rebound and SITAR-estimated latest peak height velocity in children with CAH. In addition to identifying individuals with CAH who may be at risk of adverse cardiometabolic outcomes these metrics may serve as early surrogate outcomes in future research investigating early-life treatment strategies.

#2

Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.

Seminars in thrombosis and hemostasis2026 Apr

Acquired Hemophilia A (AHA) is a rare bleeding disorder caused by factor VIII inhibitors. Standard therapies are limited by thrombotic risk and prolonged hospitalization. Emicizumab, approved for congenital Hemophilia A, has emerged as a potential alternative in AHA based on case reports and early clinical trial data. To evaluate the efficacy and safety of Emicizumab in AHA through a retrospective real-world case series and a systematic literature review with patient-level data analysis. We retrospectively analyzed five AHA cases treated with Emicizumab at two Italian centers and performed a PRISMA-compliant systematic review of published reports, extracting and analyzing patient-level data using Joanna Briggs Institute tools. In the real-world cohort, early Emicizumab use in five patients with high-titer inhibitors and severe bleeding led to rapid hemorrhagic control, early withdrawal of bypassing agents, and no thrombotic or adverse events. All five patients received immunosuppression, and inhibitor eradication was achieved in 60% of patients, but for 40% follow up is still ongoing. The literature review identified 24 patients from 18 publications. Early Emicizumab administration (at admission) was associated with reduced bleeding recurrence (0% vs. 56.3%), shorter in-hospital stay (median 23.5 days vs. 39 days), and lower bleeding-related mortality (0% vs. 12.5%) compared with delayed administration. Early Emicizumab initiation appears to be a safe and effective strategy for AHA management, particularly in fragile or high-risk populations. Its subcutaneous route, favorable safety profile, and ability to reduce hospitalization support its integration into first-line therapeutic algorithms. Further prospective studies are warranted to define.

#3

IGF-I bioavailability in congenital isolated growth hormone deficiency.

European journal of endocrinology2026 Feb 04

The Itabaianinha cohort in Brazil carries a homozygous growth hormone-releasing hormone (GHRH) receptor (GHRH-R) gene mutation, causing congenital isolated GH deficiency (GHD). Affected individuals present with severe short stature, central obesity, hypercholesterolemia, and marked reductions in serum GH, IGF-I, and IGFBP 3 concentrations yet show no premature atherosclerosis and maintain a normal lifespan. IGF-I mostly circulates bound to IGFBPs and requires proteolytic cleavage for IGF-I receptor activation. Pregnancy-associated plasma protein A (PAPP-A) is an important IGF-dependent cleavage enzyme, binding to IGFBP 4 and releasing IGF-I. PAPP-A activity is inhibited by stanniocalcin-2 (STC2). The IGFBP 4-STC2-PAPP-A axis (ISPa) has emerged as a key regulator of IGF-I bioactivity. We evaluated the ISPa in: (1) GHD subjects with homozygous GHRH-R c.57 + 1G→A mutation, (2) heterozygotes (HTZ), and (3) homozygous wild-type controls (HMZ). Parameters from the ISPa were measured at LMU Klinikum, Munich. Additional biochemical parameters were analyzed at the Federal University of Sergipe, Brazil. As expected, GHD subjects had markedly low GH, IGF-I, IGF-II, free IGF-I, and IGFBP 3 (P < .001), while HTZ resembled HMZ subjects. STC2, PAPP-A, and PAPP-A-STC2 complex concentrations did not differ between groups. However, PAPP-A2 and intact IGFBP 4 were higher in the GHD subjects (P < .05 and P < .01). Notably, IGF-I and IGFBP 3 positively correlated with IGF-II, whereas intact IGFBP 4 and PAPP-A2 showed inverse correlations with IGF-I and IGF-II. Our findings suggest altered IGF-I bioavailability regulation via the ISPa in congenital lifetime GHD, leading to increased PAPP-A2 proteolytic activity, reduced PAPP-A enzymatic activity, and reduced sequestration of PAPP-A2 by STC2.

#4

Use of Plasma-Derived FVII Concentrate in Surgical Patients with Factor VII Deficiency: A Case Series.

Seminars in thrombosis and hemostasis2026 Jan 09

Congenital factor VII (FVII) deficiency is the most common rare hemorrhagic disorder. Acquired FVII deficiency can be isolated or associated with other low coagulation factor levels. FVII levels do not accurately predict a patient's bleeding risk. In the case of surgery, the perioperative management needs to be evaluated on a case-by-case basis, considering the patient's bleeding history and the type of surgery. We present 12 patients with congenital or acquired FVII deficiency and describe the perioperative management with plasma-derived nonactivated FVII (pd-FVII) concentrate. Patients with factor VII deficiency treated with pd-FVII for perioperative hemostasis, between April 2022 and May 2025. We report thirteen procedures in 12 patients (11 males and 1 female; age range: 15-78 years). Two patients were affected by acquired deficiency, and 10 patients presented congenital deficiency. Perioperative prophylaxis with pd-FVII was performed at doses ranging from 20 to 40 IU/kg/dose. Total pd-FVII consumption ranged between 20 and 320 IU/kg. During and after surgery, there were no major bleeding or thrombotic events. In the postoperative period, only one patient presented with hematuria.

#5

Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening.

Journal of thrombosis and haemostasis : JTH2026 Mar

Rare coagulation factor deficiencies (RCFDs) can cause significant bleeding, but activated partial thromboplastin time (APTT) and prothrombin time (PT) may not detect abnormalities, and factor activity measurements do not predict bleeding severity. Thrombin generation assays may better reflect overall hemostatic capacity. This study investigated whether thrombin generation can detect RCFDs and correlate with bleeding severity in patients with congenital deficiencies of factor (F)II, FV, FV/FVIII, FVII, FX, and FXI. Thrombin generation was measured using the Nijmegen hemostasis assay in patients from the cross-sectional Dutch Rare Bleeding disorders in the Netherlands (RBiN) study (2017-2019). Parameters analyzed included thrombin potential, lag time, and thrombin potential-to-lag time (TP/LT) ratio, normalized using pooled normal plasma and expressed as percentages of the mean from 37 healthy controls. Nijmegen hemostasis assay data were correlated with bleeding severity and compared with APTT and PT. We included 106 patients, mostly with mild deficiencies (median factor activity 5%-53%). Overall, thrombin generation in patients was significantly reduced compared with controls, with decreased thrombin potentials (median 58%) and prolonged lag times (150%), resulting in reduced TP/LT ratios (45%). These parameters correlated with bleeding severity; across RCFDs, median TP/LT ratios ranged from 30% to 104% in patients without spontaneous bleeding (bleeding severity grade 0-1), 26% to 49% in mild spontaneous bleeding (grade 2), and 0% to 22% in severe spontaneous bleeding (grade 3). At 95% specificity, TP/LT ratio showed 68% to 100% sensitivity, outperforming APTT and PT (14%-80%) in all RCFDs except FVII and FV/FVIII deficiency. Thrombin generation profiling correlated with bleeding severity and showed higher sensitivity than conventional screening assays in detecting RCFDs, supporting its potential in screening and clinical evaluation of RFCDs.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2 artigos no totalmostrando 105

2026

Adiposity rebound and height velocity in patients with Congenital Adrenal Hyperplasia.

European journal of endocrinology
2025

[Protein-energy deficiency in children of the first year of life as a risk factor for dislipoproteinemia].

Voprosy pitaniia
2026

Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.

Seminars in thrombosis and hemostasis
2026

IGF-I bioavailability in congenital isolated growth hormone deficiency.

European journal of endocrinology
2026

Use of Plasma-Derived FVII Concentrate in Surgical Patients with Factor VII Deficiency: A Case Series.

Seminars in thrombosis and hemostasis
2026

Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening.

Journal of thrombosis and haemostasis : JTH
2025

Severe myelomeningocele in the fourth pregnancy of a 29-year-old woman: a case report.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2025

Clinical and Genetic Characterization of Factor XI Deficiency in Jordan: Identification of a Novel Splice-Site Mutation Associated with Severe Deficiency.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
2025

Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Systematic Review of Prevalence, Clinical Phenotype, and Surgical Outcomes.

Biomedicines
2025

Adult-onset Vitamin K-dependent Coagulation Factor Deficiency of Unidentified Etiology.

Internal medicine (Tokyo, Japan)
2025

Model-informed drug development of Mim8 - a next-generation bispecific antibody for treatment of haemophilia A.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2025

Factor XI and Atrial Fibrillation: A Mismatched Pairing?

European cardiology
2025

Deficiency of HSF4 Increases the Secretion of Small Extracellular Vesicles via Upregulation of Chaperone-Mediated Autophagy.

Journal of cellular biochemistry
2025

Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
2024

Successful Laparoscopic Sleeve Gastrectomy in a Patient With Rare Congenital Factor VII Deficiency: A Case Report and Management Strategy.

Cureus
2025

Hypercalcemia and co-occurring TBX1 mutation in Glycogen Storage Disease Type Ib: case report.

BMC medical genomics
2025

Challenges in the diagnosis and management of patients with rare coagulation disorders in Lebanon and consequences of a social and economic crisis.

Haemophilia : the official journal of the World Federation of Hemophilia
2024

[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?].

Deutsche medizinische Wochenschrift (1946)
2025

Brain Abnormalities in Young Single- and Double-Heterozygote Mice for Both Nkx2-1- and Pax8-Null Mutations.

Molecular neurobiology
2024

Clinical and Humanistic Burden of Non-inhibitor Haemophilia A in Five European Countries: Insights from the CHESS II Study.

Advances in therapy
2025

Prothrombin deficiency with recurrent subretinal hemorrhage.

Laboratory medicine
2024

Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.

Health and quality of life outcomes
2024

Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency-A large single-centre experience.

Haemophilia : the official journal of the World Federation of Hemophilia
2024

Perioperative management and neuraxial analgesia in women with factor XI deficiency (<60 IU/dL): a French multicenter observational study of 314 pregnancies.

Research and practice in thrombosis and haemostasis
2024

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside.

Current issues in molecular biology
2024

Accuracy of Glucagon Testing Across Transition in Young Adults With Childhood-Onset GH Deficiency.

The Journal of clinical endocrinology and metabolism
2024

Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.

The New England journal of medicine
2024

Updates on clinical and laboratory aspects of hereditary dyserythropoietic anemias.

International journal of laboratory hematology
2024

Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.

Journal of health economics and outcomes research
2024

Isolated Prothrombin Deficiency: A Case Report of a Rare Coagulation Disorder and Review of Literature.

Cureus
2024

Falsely prolonged prothrombin time test in a patient with erythrocytosis: a case report.

Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis
2023

Genotype-Phenotype Relationship among 785 Unrelated White Women with Inherited Congenital Factor VII Deficiency: A Three-Center Database Study.

Journal of clinical medicine
2023

PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning.

Briefings in bioinformatics
2023

Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.

International journal of molecular sciences
2023

Association between Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019) and Lupus Anticoagulant-Hypoprothrombinemia Syndrome: A Case Report and Literature Assessment.

Seminars in thrombosis and hemostasis
2023

Biomarker sST2 in Adults with Transposition of the Great Arteries Palliated by Mustard Procedure: A Five-Year Follow-up.

Pediatric cardiology
2022

Single Cell Sequencing Reveals Mechanisms of Persistent Truncus Arteriosus Formation after PDGFRα and PDGFRβ Double Knockout in Cardiac Neural Crest Cells.

Genes
2022

Congenital adiponectin deficiency mitigates high-fat-diet-induced obesity in gonadally intact male and female, but not in ovariectomized mice.

Scientific reports
2022

Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?

Human vaccines &amp; immunotherapeutics
2022

Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.

European journal of translational myology
2022

European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2022

The role of epidermal growth factor-like domain-related abnormalities, protein S Tokushima, and anti-protein S autoantibodies in pregnancy loss.

Journal of reproductive immunology
2022

Anesthesia strategy for factor X deficiency coagulopathy: case report.

Brazilian journal of anesthesiology (Elsevier)
2022

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.

The Journal of clinical endocrinology and metabolism
2021

Expanding the clinical spectrum of pathogenic variation in NR2F2: Asplenia.

European journal of medical genetics
2021

Whole Exome Sequencing Uncovered the Genetic Architecture of Growth Hormone Deficiency Patients.

Frontiers in endocrinology
2021

Biallelic P4HTM variants associated with HIDEA syndrome and mitochondrial respiratory chain complex I deficiency.

European journal of human genetics : EJHG
2021

Aldosterone signaling defect in young infants: single-center report and review.

BMC endocrine disorders
2021

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.

The Journal of clinical endocrinology and metabolism
2021

Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set.

Research and practice in thrombosis and haemostasis
2021

RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A.

Molecular therapy. Nucleic acids
2021

von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention.

Human mutation
2021

Autocrine IGF2 programmes β-cell plasticity under conditions of increased metabolic demand.

Scientific reports
2021

A pilot study on the impact of congenital thrombophilia in COVID-19.

European journal of clinical investigation
2021

Lack of resemblance between Myhre syndrome and other "segmental progeroid" syndromes warrants restraint in applying this classification.

GeroScience
2021

A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.

European journal of medical genetics
2021

Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.

Haematologica
2021

Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Molecular therapy : the journal of the American Society of Gene Therapy
2020

Genetic compensation prevents myopathy and heart failure in an in vivo model of Bag3 deficiency.

PLoS genetics
2020

Congenital Hemolytic Anemias: Is There a Role for the Immune System?

Frontiers in immunology
2020

Thyroxine Treatment During the Perinatal Stage Prevents the Alterations in the ObRb-STAT3 Leptin Signaling Pathway Caused by Congenital Hypothyroidism.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2020

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.

Blood
2019

Deficiency of NONO is associated with impaired cardiac function and fibrosis in mice.

Journal of molecular and cellular cardiology
2019

Comprehensive care for hemophilia and other inherited bleeding disorders.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
2020

Novel Intragenic PAX6 Deletion in a Pedigree with Aniridia, Morbid Obesity, and Diabetes.

Current eye research
2019

Direct Oral Anticoagulants in Patients Affected by Major Congenital Thrombophilia.

Mediterranean journal of hematology and infectious diseases
2019

Etiology of primary adrenal insufficiency in children: a 29-year single-center experience.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2019

Retinal dystrophy in an individual carrying a de novo missense variant of SMARCA4.

Molecular genetics &amp; genomic medicine
2019

Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency.

International journal of hematology
2019

Neuroglial Involvement in Abnormal Glutamate Transport in the Cochlear Nuclei of the Igf1 -/- Mouse.

Frontiers in cellular neuroscience
2019

AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).

Annals of neurology
2019

Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.

Journal of thrombosis and haemostasis : JTH
2019

Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with pd-factor VII concentrate.

Haemophilia : the official journal of the World Federation of Hemophilia
2018

Proline 36 of the Factor XIII Activation Peptide Plays a Crucial Role in Substrate Recognition and Zymogen Activation.

Thrombosis and haemostasis
2018

Site-1 protease deficiency causes human skeletal dysplasia due to defective inter-organelle protein trafficking.

JCI insight
2018

The sample that would not clot.

Clinica chimica acta; international journal of clinical chemistry
2018

Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

The American journal of surgical pathology
2018

Loss of Dis3l2 partially phenocopies Perlman syndrome in mice and results in up-regulation of Igf2 in nephron progenitor cells.

Genes &amp; development
2018

Testing for genetic contributions to infertility: potential clinical impact.

Expert review of molecular diagnostics
2018

Sclerotherapy of esophageal varices in hemophilia patients with liver cirrhosis - a prospective, controlled clinical study.

Polski przeglad chirurgiczny
2018

[Genetic factors in hypopituitarism. The role of transcription factors in pituitary hormone deficiency].

Orvosi hetilap
2018

Acquired factor V deficiency in a patient with myeloma and amyloidosis.

Thrombosis research
2018

Inherited factor II deficiency with paradoxical hypercoagulability: a case report.

Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis
2018

Anaphylaxis Following Human Prothrombin Complex Concentrate in a Child with Lupus Anticoagulant Hypoprothrombinemia Syndrome: A Cautionary Tale.

TH open : companion journal to thrombosis and haemostasis
2018

Children with premature pubarche: is an alterated neonatal 17-Ohp screening test a predictive factor?

Italian journal of pediatrics
2018

Hypothalamic abnormalities: Growth failure due to defects of the GHRH receptor.

Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2017

Factor XI gene variants in factor XI-deficient patients of Southern Italy: identification of a novel mutation and genotype-phenotype relationship.

Human genome variation
2017

Congenital Jejunal Membrane Causing Transient Pseudohypoaldosteronism and Hypoprothrombinemia in a 7-Week-Old Infant.

Klinische Padiatrie
2017

A genetic risk factor for thrombophilia in a Han Chinese family.

Molecular medicine reports
2017

Gene analysis of six cases of congenital protein S deficiency and functional analysis of protein S mutations (A139V, C449F, R451Q, C475F, A525V and D599TfsTer13).

Thrombosis research
2017

Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.

Current pharmaceutical design
2016

Minireview on Glutamine Synthetase Deficiency, an Ultra-Rare Inborn Error of Amino Acid Biosynthesis.

Biology
2017

Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia.

The Journal of pathology
2016

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia
2017

Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia
2016

Rare coagulation disorders: fibrinogen, factor VII and factor XIII.

Haemophilia : the official journal of the World Federation of Hemophilia
2016

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.

Haemophilia : the official journal of the World Federation of Hemophilia
2016

Functional characterization of a novel GFI1B mutation causing congenital macrothrombocytopenia.

Journal of thrombosis and haemostasis : JTH
2016

In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.

Circulation
2016

Autoantibodies against homocysteinylated protein in a mouse model of folate deficiency-induced neural tube defects.

Birth defects research. Part A, Clinical and molecular teratology
2017

A case of congenital prothrombin deficiency and idiopathic thrombocytopenic purpura in a pregnant female.

Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis
2016

Molecular characterization of novel splice site mutation causing protein C deficiency.

Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis
2015

Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.

European journal of clinical investigation
2015

Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.

Blood reviews
2015

Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.

Medical journal of the Islamic Republic of Iran

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Deficiência de fator II congênita.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Deficiência de fator II congênita

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Adiposity rebound and height velocity in patients with Congenital Adrenal Hyperplasia.
    European journal of endocrinology· 2026· PMID 41823987mais citado
  2. Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.
    Seminars in thrombosis and hemostasis· 2026· PMID 41534873mais citado
  3. IGF-I bioavailability in congenital isolated growth hormone deficiency.
    European journal of endocrinology· 2026· PMID 41528724mais citado
  4. Use of Plasma-Derived FVII Concentrate in Surgical Patients with Factor VII Deficiency: A Case Series.
    Seminars in thrombosis and hemostasis· 2026· PMID 41512903mais citado
  5. Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening.
    Journal of thrombosis and haemostasis : JTH· 2026· PMID 41443372mais citado
  6. Prothrombin deficiency with recurrent subretinal hemorrhage.
    Lab Med· 2025· PMID 39079028recente
  7. Association between Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019) and Lupus Anticoagulant-Hypoprothrombinemia Syndrome: A Case Report and Literature Assessment.
    Semin Thromb Hemost· 2023· PMID 36807282recente
  8. A pilot study on the impact of congenital thrombophilia in COVID-19.
    Eur J Clin Invest· 2021· PMID 33738814recente
  9. Inherited factor II deficiency with paradoxical hypercoagulability: a case report.
    Blood Coagul Fibrinolysis· 2018· PMID 29389674recente
  10. Congenital Jejunal Membrane Causing Transient Pseudohypoaldosteronism and Hypoprothrombinemia in a 7-Week-Old Infant.
    Klin Padiatr· 2017· PMID 28806843recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:325(Orphanet)
  2. OMIM OMIM:613679(OMIM)
  3. MONDO:0013361(MONDO)
  4. GARD:2926(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q3801629(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Deficiência de fator II congênita
Compêndio · Raras BR

Deficiência de fator II congênita

ORPHA:325 · MONDO:0013361
Prevalência
<1 / 1 000 000
Herança
Autosomal recessive
CID-10
D68.2 · Deficiência hereditária de outros fatores de coagulação
CID-11
Início
All ages
Prevalência
0.05 (Europe)
MedGen
UMLS
C0020640
EuropePMC
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades